research The Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-positive Breast Cancer Who Are on Adjuvant Aromatase Inhibitor Therapy: Meta-analysis
This meta-analysis found that in postmenopausal women with a history of breast cancer, 8 weeks of vaginal estrogen therapy while on aromatase inhibitors did not result in systemic absorption of sex hormones, suggesting potential safety for treating vulvovaginal atrophy in this context.

